Toward a gene therapy for neurological and somatic MPSIIIA

References

• Valstar MJ, Ruijter GJ, van Diggelen OP, Poorthuis BJ, Wijburg FA. Sanfilippo syndrome: a mini-review. J Inherit Metab Dis 2008; 31:240 - 52; http://dx.doi.org/10.1007/s10545-008-0838-5; PMID: 18392742
   PubMed Web of Science ®Google Scholar
• Meyer A, Kossow K, Gal A, Mühlhausen C, Ullrich K, Braulke T, Muschol N. Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A). Pediatrics 2007; 120:e1255 - 61; http://dx.doi.org/10.1542/peds.2007-0282; PMID: 17938166
   PubMed Web of Science ®Google Scholar
• Valstar MJ, Neijs S, Bruggenwirth HT, Olmer R, Ruijter GJ, Wevers RA, van Diggelen OP, Poorthuis BJ, Halley DJ, Wijburg FA. Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations. Ann Neurol 2010; 68:876 - 87; http://dx.doi.org/10.1002/ana.22092; PMID: 21061399
   PubMed Web of Science ®Google Scholar
• Enns GM, Huhn SL. Central nervous system therapy for lysosomal storage disorders. Neurosurg Focus 2008; 24:E12; http://dx.doi.org/10.3171/FOC/2008/24/3-4/E11; PMID: 18341388
   PubMedGoogle Scholar
• Sondhi D, Johnson L, Purpura K, Monette S, Souweidane MM, Kaplitt MG, Kosofsky B, Yohay K, Ballon D, Dyke J, et al. Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis. Hum Gene Ther Methods 2012; 23:324 - 35; http://dx.doi.org/10.1089/hgtb.2012.120; PMID: 23131032
   PubMed Web of Science ®Google Scholar
• Haurigot V, Marcó S, Ribera A, Garcia M, Ruzo A, Villacampa P, Ayuso E, Añor S, Andaluz A, Pineda M, et al. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Invest 2013; 128:3254 - 71; http://dx.doi.org/10.1172/JCI66778; PMID: 23863627
   PubMed Web of Science ®Google Scholar
• Ciron C, Cressant A, Roux F, Raoul S, Cherel Y, Hantraye P, Déglon N, Schwartz B, Barkats M, Heard JM, et al. Human alpha-iduronidase gene transfer mediated by adeno-associated virus types 1, 2, and 5 in the brain of nonhuman primates: vector diffusion and biodistribution. Hum Gene Ther 2009; 20:350 - 60; http://dx.doi.org/10.1089/hum.2008.155; PMID: 19272011
   PubMed Web of Science ®Google Scholar
• Colle MA, Piguet F, Bertrand L, Raoul S, Bieche I, Dubreil L, Sloothaak D, Bouquet C, Moullier P, Aubourg P, et al. Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate. Hum Mol Genet 2010; 19:147 - 58; http://dx.doi.org/10.1093/hmg/ddp475; PMID: 19837699
   PubMed Web of Science ®Google Scholar
• Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009; 27:59 - 65; http://dx.doi.org/10.1038/nbt.1515; PMID: 19098898
   PubMed Web of Science ®Google Scholar
• Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, Douar AM, Fyfe J, Moullier P, Colle MA, Barkats M. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 2009; 17:1187 - 96; http://dx.doi.org/10.1038/mt.2009.71; PMID: 19367261
   PubMed Web of Science ®Google Scholar
• Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 2011; 12:341 - 55; http://dx.doi.org/10.1038/nrg2988; PMID: 21499295
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365:2357 - 65; http://dx.doi.org/10.1056/NEJMoa1108046; PMID: 22149959
   PubMed Web of Science ®Google Scholar
• Buchlis G, Podsakoff GM, Radu A, Hawk SM, Flake AW, Mingozzi F, High KA. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood 2012; 119:3038 - 41; http://dx.doi.org/10.1182/blood-2011-09-382317; PMID: 22271447
   PubMed Web of Science ®Google Scholar
• Souweidane MM, Fraser JF, Arkin LM, Sondhi D, Hackett NR, Kaminsky SM, Heier L, Kosofsky BE, Worgall S, Crystal RG, et al. Gene therapy for late infantile neuronal ceroid lipofuscinosis: neurosurgical considerations. J Neurosurg Pediatr 2010; 6:115 - 22; http://dx.doi.org/10.3171/2010.4.PEDS09507; PMID: 20672930
   PubMed Web of Science ®Google Scholar
• Ciron C, Desmaris N, Colle MA, Raoul S, Joussemet B, Vérot L, Ausseil J, Froissart R, Roux F, Chérel Y, et al. Gene therapy of the brain in the dog model of Hurler’s syndrome. Ann Neurol 2006; 60:204 - 13; http://dx.doi.org/10.1002/ana.20870; PMID: 16718701
   PubMed Web of Science ®Google Scholar
• Leone P, Shera D, McPhee SW, Francis JS, Kolodny EH, Bilaniuk LT, Wang DJ, Assadi M, Goldfarb O, Goldman HW, et al. Long-term follow-up after gene therapy for canavan disease. Sci Transl Med 2012; 4:ra163; http://dx.doi.org/10.1126/scitranslmed.3003454; PMID: 23253610
   PubMed Web of Science ®Google Scholar
• Worgall S, Sondhi D, Hackett NR, Kosofsky B, Kekatpure MV, Neyzi N, Dyke JP, Ballon D, Heier L, Greenwald BM, et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther 2008; 19:463 - 74; http://dx.doi.org/10.1089/hum.2008.022; PMID: 18473686
   PubMed Web of Science ®Google Scholar
• Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, VanBrocklin HF, Wright JF, Bankiewicz KS, Aminoff MJ. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009; 73:1662 - 9; http://dx.doi.org/10.1212/WNL.0b013e3181c29356; PMID: 19828868
   PubMed Web of Science ®Google Scholar
• Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet 2007; 369:2097 - 105; http://dx.doi.org/10.1016/S0140-6736(07)60982-9; PMID: 17586305
   PubMed Web of Science ®Google Scholar
• Marks WJ Jr., Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, Vitek J, Stacy M, Turner D, Verhagen L, et al. Gene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010; 9:1164 - 72; http://dx.doi.org/10.1016/S1474-4422(10)70254-4; PMID: 20970382
   PubMed Web of Science ®Google Scholar
• Brain Development Cooperative Group. Total and regional brain volumes in a population-based normative sample from 4 to 18 years: the NIH MRI Study of Normal Brain Development. Cereb Cortex 2012; 22:1 - 12; http://dx.doi.org/10.1093/cercor/bhr018; PMID: 21613470
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, et al. AAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 2011; 10:309 - 19; http://dx.doi.org/10.1016/S1474-4422(11)70039-4; PMID: 21419704
   PubMed Web of Science ®Google Scholar
• Colpan ME, Slavin KV. Subthalamic and red nucleus volumes in patients with Parkinson’s disease: do they change with disease progression?. Parkinsonism Relat Disord 2010; 16:398 - 403; http://dx.doi.org/10.1016/j.parkreldis.2010.03.008; PMID: 20452266
   PubMed Web of Science ®Google Scholar
• Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr., Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, et al. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med 2008; 358:2240 - 8; http://dx.doi.org/10.1056/NEJMoa0802315; PMID: 18441370
   PubMed Web of Science ®Google Scholar
• Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F, Mingozzi F, Bennicelli JL, Ying GS, Rossi S, et al. Age-dependent effects of RPE65 gene therapy for Leber’s congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009; 374:1597 - 605; http://dx.doi.org/10.1016/S0140-6736(09)61836-5; PMID: 19854499
   PubMed Web of Science ®Google Scholar
• Hermann DS. Anatomy of the globe, Basic and Clinical Science Course. AAO, 2009: 43-92.
   Google Scholar
• Galea I, Bechmann I, Perry VH. What is immune privilege (not)?. Trends Immunol 2007; 28:12 - 8; http://dx.doi.org/10.1016/j.it.2006.11.004; PMID: 17129764
   PubMed Web of Science ®Google Scholar
• Piatt JHBK. Technique of Ventriculostomy, In: Rengachary S WR, ed. Neurosurgical Operative Atlas. Chicago: The American Association of Neurological Surgeons, 1991: 171-5.
   Google Scholar
• Cook AM, Mieure KD, Owen RD, Pesaturo AB, Hatton J. Intracerebroventricular administration of drugs. Pharmacotherapy 2009; 29:832 - 45; http://dx.doi.org/10.1592/phco.29.7.832; PMID: 19558257
   PubMed Web of Science ®Google Scholar
• American Association of Neurological Surgeons. National Neurosurgical Procedural Statistics.2006 Survey, In: AANS, ed. Meadows, IL: American Association of Neurological Surgeons, 2006
   Google Scholar
• Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12:342 - 7; http://dx.doi.org/10.1038/nm1358; PMID: 16474400
   PubMed Web of Science ®Google Scholar
• Scallan CD, Jiang H, Liu T, Patarroyo-White S, Sommer JM, Zhou S, Couto LB, Pierce GF. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood 2006; 107:1810 - 7; http://dx.doi.org/10.1182/blood-2005-08-3229; PMID: 16249376
   PubMed Web of Science ®Google Scholar
• Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, Masurier C. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 2010; 21:704 - 12; http://dx.doi.org/10.1089/hum.2009.182; PMID: 20095819
   PubMed Web of Science ®Google Scholar
• Calcedo R, Morizono H, Wang L, McCarter R, He J, Jones D, Batshaw ML, Wilson JM. Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin Vaccine Immunol 2011; 18:1586 - 8; http://dx.doi.org/10.1128/CVI.05107-11; PMID: 21775517
   PubMed Web of Science ®Google Scholar
• Li C, Narkbunnam N, Samulski RJ, Asokan A, Hu G, Jacobson LJ, Manco-Johnson MJ, Monahan PE, Joint Outcome Study Investigators. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Ther 2012; 19:288 - 94; http://dx.doi.org/10.1038/gt.2011.90; PMID: 21697954
   PubMed Web of Science ®Google Scholar
• Ruzo A, Marcó S, García M, Villacampa P, Ribera A, Ayuso E, Maggioni L, Mingozzi F, Haurigot V, Bosch F. Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer. Hum Gene Ther 2012; 23:1237 - 4; http://dx.doi.org/10.1089/hum.2012.029; PMID: 22909060
   PubMed Web of Science ®Google Scholar
• Fu H, Dirosario J, Killedar S, Zaraspe K, McCarty DM. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol Ther 2011; 19:1025 - 33; http://dx.doi.org/10.1038/mt.2011.34; PMID: 21386820
   PubMed Web of Science ®Google Scholar
• Ruzo A, Garcia M, Ribera A, Villacampa P, Haurigot V, Marcó S, Ayuso E, Anguela XM, Roca C, Agudo J, et al. Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice. Mol Ther 2012; 20:254 - 66; http://dx.doi.org/10.1038/mt.2011.220; PMID: 22008915
   PubMed Web of Science ®Google Scholar
• Crawley AC, Gliddon BL, Auclair D, Brodie SL, Hirte C, King BM, Fuller M, Hemsley KM, Hopwood JJ. Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA. Brain Res 2006; 1104:1 - 17; http://dx.doi.org/10.1016/j.brainres.2006.05.079; PMID: 16828069
   PubMed Web of Science ®Google Scholar
• Hemsley KM, Hopwood JJ. Development of motor deficits in a murine model of mucopolysaccharidosis type IIIA (MPS-IIIA). Behav Brain Res 2005; 158:191 - 9; http://dx.doi.org/10.1016/j.bbr.2004.08.019; PMID: 15698885
   PubMed Web of Science ®Google Scholar
• Biffi A, Capotondo A, Fasano S, del Carro U, Marchesini S, Azuma H, Malaguti MC, Amadio S, Brambilla R, Grompe M, et al. Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. J Clin Invest 2006; 116:3070 - 82; http://dx.doi.org/10.1172/JCI28873; PMID: 17080200
   PubMed Web of Science ®Google Scholar